|
City of Hope |
|
Atara Bio. |
Cancer - Nasopharyngeal Carcinoma |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
No longer active |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) |
No longer active |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) |
No longer active |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Long-Term Follow-up Study for Patients Previously Treated With JCAR015 |
No longer active |
|
|
UC Davis |
|
Medeor Therapuetics |
Kidney Transplant |
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants |
No longer active |
|
|
UC Davis |
|
Capricor Therapeutics |
COVID |
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19 |
No longer active |
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in P |
|
UC Davis |
|
Kite Pharma |
Advanced Cancer |
A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers |
No longer active |
|
|
UC Davis |
|
Atara Bio. |
EBV-PTLD |
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
No longer active |
|
|
UC Davis |
|
Capricor Therapeutics |
Muscle - Duchenne Muscular Dystrophy |
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) |
No longer active |
|
|
UC Davis |
|
Nohla Therapeutics |
Cancer – Leukemia |
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML |
No longer active |
|
|
UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
|
UCI |
|
ImmunoCellular Therapeutics |
Cancer - Brain |
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma |
No longer active |
|
|
UCI |
|
SanBio |
Stroke |
Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke |
No longer active |
|
|
UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
|
UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
No longer active |
|
|
UCLA |
|
UCLA |
Cancer |
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) |
No longer active |
|
|
UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens |
No longer active |
|
|
UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
|
UCSD |
|
UCSD |
Cancer - Leukemia |
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 |
No longer active |
|
|
UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) |
No longer active |
|
|
UCSD |
|
Asterias Biotherapeutics |
Spinal Cord Injury |
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
No longer active |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Sarcoma |
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma |
Active, not recruiting |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma (AIDS-Related) |
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
Active, not recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
|
|
UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
UCI
& UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Active, not recruiting |
|
UCI
& UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
Active, not recruiting |
|
|
UCI |
|
Stratetech |
Burn wounds |
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
Active, not recruiting |
|
UCLA
& UCI |
|
SanBio |
Brain Injury |
A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) |
Active, not recruiting |
|
|
UCLA |
|
Orchard Therapeutics |
Severe Combined Immunodeficiency (SCID) |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency |
Active, not recruiting |
|
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus |
Active, not recruiting |
|
|
UCSD |
|
UCSD |
Cancer - Breast |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Active, not recruiting |
|
|
UCSD |
|
Discgenics |
Degenerative Disc Disease |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
Active, not recruiting |
|
|
UCSD |
|
Aivita |
Ovarian and Fallopian Tube Carcinoma |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas |
Active, not recruiting |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcino |
|
UCSD |
|
Fate Therapeutics |
Solid tumors |
FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors |
Active, not recruiting |
FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors |
|
UCSF |
|
bluebird bio |
Sickle Cell Disease |
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease |
Active, not recruiting |
NCT02140554 |
UCSF
& UC Davis |
|
Poseida Therapeutics, Inc. |
Multiple Myeloma |
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) |
Active, not recruiting |
NCT03288493 |
|
City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC |
Recruiting |
|
|
City of Hope |
|
Angiocrine Bioscience |
Cancer - Leukemia |
A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation |
Recruiting |
|
|
City of Hope |
|
Celgene |
Cancer - Lymphoma |
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Ovarian |
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. |
Recruiting |
|
|
City of Hope |
|
Torque Therapeutics, Inc. |
Cancer - Lymphoma |
TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas |
Recruiting |
|
|
City of Hope |
Elizabeth Budde, MD
626-218-2405 |
Kite Pharma |
Cancer - Lymphoma |
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma |
Recruiting |
|
|
City of Hope |
|
Sangamo Therapeutics |
Hemophilia B |
Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B |
Recruiting |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma |
Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Sickle Cell Disease |
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant |
Recruiting |
|
